Cancer Research Meeting Calendar Jordan
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Casati, C.
Right arrow Articles by Castelli, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Casati, C.
Right arrow Articles by Castelli, C.
[Cancer Research 66, 4450-4460, April 15, 2006]
© 2006 American Association for Cancer Research

Immunology

Soluble Human LAG-3 Molecule Amplifies the In vitro Generation of Type 1 Tumor-Specific Immunity

Chiara Casati1, Chiara Camisaschi1, Francesca Rini1, Flavio Arienti2, Licia Rivoltini1, Frédéric Triebel3, Giorgio Parmiani1 and Chiara Castelli1

Units of 1 Immunotherapy of Human Tumors and 2 Immunohematology, Istituto Nazionale Tumori, Milan, Italy and 3 Immutep S.A., Faculté de Pharmacie, Châtenay-Malabry, France

Requests for reprints: Giorgio Parmiani, Unit of Immunotherapy of Human Tumors, Department of Experimental Oncology, Istituto Nazionale Tumori, via G. Venezian 1, 20133 Milan, Italy. Phone: 39-02-2390-2328; Fax: 39-02-2390-2630; E-mail: giorgio.parmiani{at}istitutotumori.mi.it.


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
The adjuvant activities of the human lymphocyte activation gene-3 (LAG-3) molecule have been evaluated in a human setting by investigating the ability of a soluble recombinant human LAG-3 protein (hLAG-3Ig) to enhance the in vitro induction of viral- and tumor-specific CTLs. We found that soluble human LAG-3 significantly sustained the generation and expansion of influenza matrix protein Melan-A/MART-1 and survivin-specific CD8+ T lymphocytes in peripheral blood mononuclear cells (PBMC) of both cancer patients and healthy donors, showing its ability to boost CD8+ T-cell memory response or to prime naive T cells in vitro. The peptide-specific T cells generated in the presence of hLAG-3Ig were endowed with cytotoxic activity and enhanced release of type 1 cytotoxic T (Tc1) cytokines and were able to recognize tumor cells expressing their nominal antigen. Phenotype and cytokine/chemokines produced by antigen-presenting cells (APC) of PBMCs exposed in vitro for 2 days to peptide and hLAG-3Ig indicate that the LAG-3–mediated adjuvant effect may depend on a direct activation of circulating APCs. Our data revealed the activity of hLAG-3Ig in inducing tumor-associated, antigen-specific CD8+ T-cell responses in a human setting and strongly support the conclusion that this recombinant protein is a potential candidate adjuvant for cancer vaccines. (Cancer Res 2006; 66(8): 4450-60)


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
The ability to induce a strong immune response that includes the generation and expansion of tumor-specific cytotoxic T cells is indeed the first requirement for a clinically effective cancer vaccine (1). However, the nature of tumor-associated antigens (TAA), which are mainly self-derived proteins to which the immune system could be tolerized, is a major critical issue hampering the success of cancer immunotherapy. To induce sustained systemic immune responses, several strategies have been developed, and besides the variety of vaccine formulations, the efficacy of different immunologic adjuvants has been investigated (2). Although vaccine adjuvants have become of general use, and some of them have been extensively exploited in preclinical and clinical approaches, their mechanisms of action are not yet completely understood. Nevertheless, it is now clear that adjuvants can exert their effects at different stages of vaccine-induced immunologic responses; most of them work mainly by activating and licensing dendritic cells to present antigens in a correct activating milieu (3). Vaccine strategy should also be effective in sustaining the final effector phase of the T-cell response. Several mechanisms arising both from tumor and from immune system itself have been recently described, which can impair the activity of antitumor T cells (4, 5), and one of the most relevant suppressor mechanisms is operated by regulatory T cells (6–8). The overcome of this negative immune-related feedback is indeed a challenging issue that should be taken into consideration in designing new therapeutic cancer strategies. Given the complexity in the generation of a strong and effective response against tumors, the identification and the development of new immunologic adjuvants is, therefore, mandatory.

Lymphocyte activation gene-3 (LAG-3) is a member of immunoglobulin superfamily (9) that binds MHC class II molecules (10). It is expressed on activated natural killer and T cells but not on resting T lymphocytes (9, 11). A complex role of LAG-3 in controlling T-cell functions has been recently reported in murine and in human setting (12). Like CD4 and CD8, LAG-3 is associated with the CD3/TCR complex and shown to be involved in down-regulating antigen-induced TCR signaling (13, 14). Recent studies in mice (15, 16) and in humans (17) reported that LAG-3 negatively regulates T-cell function and homeostasis. However, as a soluble molecule, LAG-3 activates antigen-presenting cells (APC) through MHC class II signaling (18, 19), leading to increased antigen-specific T-cell responses in vivo (20), and its presence as free molecule in the sera of subgroups of breast cancer patients at diagnosis has been correlated with a better survival (21). Given these critical roles of the protein in the immune system, its physiologic expression in human tumor-infiltrating lymphocytes (22) and its ability to activate APCs in vitro, soluble LAG-3 molecule has been exploited as a vaccine adjuvant in in vivo mouse models, by using either viral-associated antigens or TAAs given as irradiated LAG-3-transfected syngeneic tumor cells, soluble proteins, or as gene-encoding plasmids (20, 23, 24). Vaccination in the presence of LAG-3 induced a strong adjuvant activity and the generation of a protective long-lasting immunity. However, immunologic mechanisms by which LAG-3 molecule exerts its adjuvant actions have not been studied using complex, physiologically relevant cell populations, such as peripheral blood mononuclear cell (PBMC) and tumor antigens. In the present study, we evaluated the adjuvant effect of human soluble LAG-3 protein in a human setting by investigating its ability to enhance the induction of viral- and tumor-specific CTLs in PBMCs of cancer patients and healthy donors.

Both viral and tumor antigen models were used: the highly immunogenic influenza matrix protein–derived peptide Flu58-66, the melanoma-associated peptide MART27-35, its MART26-35A27L analogue, and the survivin-derived SVV-195-104 peptide. For the first time, we showed that soluble human LAG-3 significantly sustained the generation and the expansion of influenza matrix protein Melan-A/MART-1 and survivin-specific CD8+ T lymphocytes both in melanoma or colorectal cancer patients and in healthy donors, showing a double ability to boost CD8+ T-cell memory response and to prime naive T cells. The generated T cells were endowed with cytotoxic activity and a Tc1 cytokine secretion profile. The LAG-3-mediated adjuvant effect was shown also in CD4+CD25+-depleted PBMCs, and it might partially rely on direct activation of APCs residing in human peripheral blood that include monocytes, B cells, and dendritic cells. Thus, we were able to show for the first time that the human LAG-3 molecule supported the generation and increased the frequency of tumor-specific CD8+ T-cell responses in the human immune system, therefore validating the use of this protein as a potential adjuvant in immunotherapeutic approaches against cancer.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Reagents. The recombinant soluble human LAG-3 fusion protein (hLAG-3Ig) identified as the product IMP321 was provided by Immutep (Orsay, France) from a pre-GMP batch. Briefly, Chinese hamster ovary DHFR– cells were transfected with a plasmid coding for the D1-D4 extracellular domains of hLAG-3 fused to the Fc tail of a hIgG1 (25). A productive clone was selected after amplification in methothrexate. The purified bulk preclinical batch has a concentration of 1.89 mg/mL hLAG-3Ig in the form of a 200-kDa dimeric protein and 0.75 EU/mg endotoxin (LAL assay, Bio Whittaker, Walkersville, MD), 0.42 ng/mL DNA, and 6 ng/mL host cell protein contents. An aliquot of the hLAG-3Ig preparation used throughout this study has been analyzed by SDS-PAGE, and gels were stained with Coomassie blue or blotted on polyvinyl difluoride membrane (Bio-Rad Laboratories, Richmond, CA) and hybridized with anti human-LAG-3 mouse monoclonal antibody (mAb) 17B4 (see Supplementary Fig. S1) followed by goat anti-mouse horseradish peroxidase IgG (Calbiochem, Darmstadt, Germany). Boiling hLAG-3Ig for 5 minutes abrogated its biological activity, evaluated as the ability to up-regulate CD83 expression on monocytes purified from PBMCs of healthy donors.

Peptide synthesis. Peptides were purchased from Immatics (Tübingen, Germany); their degree of purification was analyzed by high-performance liquid chromatography. All the peptides showed >95% purity. The following peptides were used in this study: survivin-derived SVV-195-104 (ELTLGEFLKL), MelanA/MART-1–derived MART27-35 (AAGIGILTV) and MART26-35A27L (ELAGIGILTV), influenza matrix protein–derived Flu58-66 (GILGFVFTL), and HIV envelope–derived HIVenv117-125 (KLTPLCVTL).

Antigen stimulation of peripheral blood lymphocytes. Upon informed consent, blood samples were collected from melanoma and colorectal cancer patients or healthy donors. PBMCs were isolated and analyzed for HLA-A*0201 expression as previously described (26).

On day 0, PBMCs were seeded in 24-well plates at a concentration of 106/mL in RPMI 1640, supplemented with 10% heat-inactivated human serum, 2 mmol/L L-glutamine (Bio Whittaker Europe, Verviers, Belgium), and antibiotics. To induce the generation of peptide-specific CD8+ T lymphocytes, cells were stimulated for 10 days with the indicated peptide at a concentration of 2 µg/mL (Flu58-66) or 3 µg/mL (MART26-35A27L, MART27-35, or SVV-1), with or without 16 µg/mL hLAG-3Ig. As control, induction of peptide-specific T cells was also done in the presence of 16 µg/mL of human IgG, Fc fragment–purified protein, or human IgG, whole molecule purified protein (Chemicon International, Temecula, CA). On day 2, interleukin 2 (IL-2; EuroCetus, Amsterdam, the Netherlands) was added at a final concentration of 60 IU/mL; then cells were maintained under the same conditions, replacing half of the medium and IL-2 every 2 days. For experiments aimed at evaluating the effect of hLAG-3Ig on APCs, supernatants were collected and stored after 48 hours of cell culture, and cells were harvested and analyzed for the surface expression of activation markers. If required, restimulation was done using autologous PBMCs at a stimulator/responder ratio of 4:1, pulsed with peptide either alone or in the presence of 16 µg/mL hLAG-3Ig for 2 hours, and then {gamma}-irradiated (3,000 rad).

Depletion of CD4+CD25+ T cells from freshly isolated PBMCs was done by immunomagnetic sorting with a human CD4+CD25+ Isolation kit following the manufactory instructions (Miltenyi Biotech, Bergisch Gladbach, Germany). Depleted cells were stimulated at the same experimental conditions set for the whole PBMC population (see above). When needed, restimulation was conducted using CD4+CD25+-depleted, peptide-pulsed, {gamma}-irradiated autologous PBMCs at a stimulator/responder ratio of 4:1.

T-cell stimulation assay. The presence of an antigen-specific CD8+ T-cell response was first detected by evaluating IFN-{gamma} release in a T-cell stimulation assay. HLA-A*0201+ T2 cells were pulsed for 2 hours at 37°C with 2 µg/mL of the stimulating peptide and of a control HIV-derived epitope (HIV env117-125, HLA-A*0201 restricted). For experiments aimed at evaluating the presence of a CD8+ T cell response against TAAs (Melan-A/MART-1 and survivin), HLA-A*0201+ tumor cells were also used as a target. In particular, Melan-A/MART-1-specific T-cell response was analyzed by using the HLA-A*0201+ Melan-A/MART-1+ Me501 melanoma cell line (generated in our laboratory from tissue obtained from a metastatic melanoma patient); the survivin+, HLA-A*0201+ SW480 colon cancer cell line (American Type Culture Collection, Rockville, MD) was used as a target for survivin-specific T cells. Inhibition experiments were done by adding to tumor cells 1 µg/mL of anti-class I HLA A6-136 mAb.

IFN-{gamma} and perforin enzyme-linked immunospot. Evaluation of IFN-{gamma} and Perforin release by stimulated T cells was done by using the enzyme-linked immunospot (ELISPOT) method, as previously described (25). A detailed description of the protocol used in this study for the detection of both proteins is provided in the Supplementary Data.

Cytometric bead array assay. To simultaneously detect and measure multiple soluble analytes released in the supernatants of cell cultures, the Becton Dickinson Cytometric Bead Array (CBA) was used in this study. Each assay was conducted according to the manufactory instructions. See Supplementary Data for details.

Tetramer staining. Staining of Melan-A/MART-1- or Flu-specific T cells was done using commercially available phycoerythrin-conjugated HLA-A*0201/MART26-35A27L and HLA-A*0201/Flu58-66 tetramers (Immunomics, Beckman Coulter, Marseilles, France). Briefly, 5 x 105 stimulated T cells were incubated for 45 minutes at 4°C with 10 µL of tetramer, then washed twice in PBS, and incubated for 30 minutes at 4°C with anti-CD8 mAb (Becton Dickinson, Heidelberg, Germany). Fluorescence intensity was evaluated using a FACSCalibur flow cytometer and analyzed using CellQuest software (Becton Dickinson). A phycoerythrin-conjugated HLA-A*0201-negative tetramer (Immunomics, Beckman Coulter) was used as a control (data not shown).

Flow cytometric immunofluorescence analysis. Evaluation of APC activation in whole PBMC populations was done by flow cytometry. To specifically identify and enumerate peripheral blood monocytes and B cells, alternative staining with FITC-conjugated CD14 or CD19 mAb was done: cells resulting positive for either marker were analyzed for the surface expression of CD80, CD83, and CD86 proteins by using phycoerythrin-conjugated mAb (all purchased from Becton Dickinson). Peripheral blood dendritic cells (PBDC) were identified as lineage (CD3, CD14, CD16, CD19, CD20, CD56) negative and CD123low/high and then analyzed for the surface expression of CD80, CD83, and CD86 proteins by using phycoerythrin-conjugated mAb. Fluorescence intensity was evaluated using a FACSCalibur flow cytometer and analyzed using CellQuest software (Becton Dickinson).


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Soluble human LAG-3 enhances the expansion of tumor- or viral-specific CD8+ T lymphocytes. To evaluate the ability of LAG-3-soluble molecule to enhance the priming of naive CD8+ T cells or to boost a CD8+ memory T-cell response, four different antigen models have been used that include the influenza matrix protein–derived Flu58-66 peptide, the TAA peptide MART27-35, its MART26-35A27L analogue, and the survivin-derived SVV-195-104 peptide. PBMCs from healthy donors were used as responder cells, being known that whereas influenza-specific CD8+ T cells carry features of antigen-experienced T cells, anti-Melan-A/MART-1 CD8+ T cells in healthy individuals all belong to the naive T-cell subset. Moreover, activities of LAG-3 molecule in association with tumor-derived peptides were also tested in cancer patient PBMCs. Circulating CD8+ T cells specific for tumor antigens in cancer patients include T cells belonging to both memory and naive compartments, as shown for Melan-A/MART-1 (27). In addition, in view of a possible usage of LAG-3-soluble molecule in cancer vaccine, it was crucial to test its biological functions using TAAs and patients' derived PBMCs as responder cells.

PBMCs from HLA-A*0201+ donors were stimulated in vitro with the Flu58-66 peptide (GILGFVFTL), with the wild-type MART27-35 nonapeptide (AAGIGILTV), or with the highly immunogenic MART26-35A27L peptide analogue (ELAGIGILTV), whereas melanoma or colon cancer patients' PBMCs were stimulated with the two mentioned Melan-A/MART-1 peptides and with the survivin-derived SVV-195-104 peptide (ELTLGEFLKL), respectively. In vitro stimulation was done in the presence or absence of 16 µg/mL of LAG-3 recombinant protein (hLAG-3Ig), and functional and phenotypic analysis of the peptide-sensitized T cells was conducted after 1 or 2 weeks of in vitro culture.

Proliferation of each cell culture was monitored by counting the total number of lymphocytes in the single culture conditions at different time points.

We found that the addition of hLAG-3Ig induced an expansion of the cultured lymphocytes for all the peptides used (Fig. 1 ), whereas the total number of cells remained unchanged when the in vitro stimulation was done with peptide alone. This LAG-3-dependent proliferation started early during the in vitro culture, being detectable at day 10 of culture. Moreover, the difference in the yield of the peptide-stimulated T cells was amplified after the second week of culture, and all the T cells grown in the presence of hLAG-3Ig showed a fold increase ranging from 2.5 (Fig. 1A and E) to 6 (Fig. 1C and F).


Figure 1
View larger version (15K):
[in this window]
[in a new window]
  		Figure 1. hLAG-3Ig increased the proliferation of antigen-stimulated PBMCs. PBMCs from healthy donors (A, B, and E), melanoma patients (C and D), and colorectal cancer patients (F) were stimulated once or twice with the indicated peptide, either alone (gray lines) or in the presence of 16 µg/mL hLAG-3Ig (black lines), and their growth was monitored at various time points. Data report the overall number of T lymphocytes present in each cell culture at the indicated time points. Six independent T-cell cultures representative of a total of 20 have been reported.

 
We next asked whether this strong proliferative response achieved in the presence of hLAG-3Ig was also associated with an increase in the number of peptide-specific T cells. Therefore, we evaluated the presence and frequency of antigen-specific CD8+ T lymphocytes after one or two rounds of peptide stimulation by using antigen-specific tetramer staining. We found that the addition of hLAG-3Ig induced a significant increase of the frequency of antigen-specific CD8+ T cells in all the in vitro cultures.

PBMCs of HLA-A*0201+ healthy donors, stimulated with the influenza matrix protein–derived Flu58-66 peptide, showed an increased frequency of peptide-specific, CD8+ T lymphocytes when cultured in the presence of hLAG-3Ig as detected by staining with the HLA-A*0201/Flu58-66 tetramer (Fig. 2A , donors D1 and D2), and this difference was amplified after a second round of stimulation (Fig. 2A, donor D3).


Figure 2
View larger version (23K):
[in this window]
[in a new window]
  		Figure 2. Tetramer-guided analysis of antigen-specific CD8+ T cells. PBMCs from healthy donors were stimulated with Flu58-66 peptide (A: D1, D2, one round of stimulation; D3, two rounds of stimulation), with MART26-35A27L analogue peptide (B: D4 and D5, two rounds of stimulation), and with MART27-35 wild-type nonapeptide (C: D4 and D5, two rounds of stimulation) either alone (left) or in the presence of 16 µg/mL hLAG-3Ig (right). After staining with FITC-conjugated anti-CD8 mAb and phycoerythrin-conjugated Flu58-66/HLA-A*0201 tetramers (A) or PE-conjugated MART26-35A27L/HLA-A*0201 tetramers (B and C), the percentage of CD8+, peptide-specific T cells was determined by flow cytometry (see top right quadrant of each dot plot). PBMCs from melanoma patients P1 and P2 were subjected to two rounds of in vitro stimulation with MART26-35A27L analogue peptide (D) or with the MART27-35 wild-type nonapeptide (E) either alone (left) or with the addition of 16 µg/mL hLAG-3Ig (right). After staining with phycoerythrin-conjugated MART26-35A27L/HLA-A*0201 tetramers and FITC-conjugated anti-CD8 mAb (D and E), the percentage of CD8+, antigen-specific T lymphocytes was determined by flow cytometry (see top right quadrant of each dot plot).

 
A similar effect in healthy donors' PBMCs was seen also when considering the induction of Melan-A/MART-1–specific T-cell responses. HLA-A*0201+ T lymphocytes stimulated with the highly immunogenic decapeptide MART26-35A27L exhibited a significant increase of epitope-specific CD8+ T cells when cultured with hLAG-3Ig. In fact, the frequency of CD8+, HLA-A*0201/MART26-35A27L tetramer-positive cells reached the 27.66% or 32.87% for hLAG-3Ig/peptide–stimulated cells compared with a 1.24% or 0.42% frequency when the same PBMCs were stimulated in the absence of hLAG-3Ig (Fig. 2B, donors D4 and D5). Although the total number of specific T cells was lower, the same trend was also observed for the less immunogenic wild-type MART27-35 nonapeptide, with frequency values obtained with hLAG-3Ig showing almost 2-fold increase in respect to that achieved after stimulation with the peptide alone (Fig. 2C). Thus, the adjuvant effect of hLAG-3Ig on peptide-stimulated T cells was observed for PBMCs of healthy donors both with viral- and melanoma-associated antigen, suggesting a role for this molecule in a general mechanism of activation, regardless of the naive or effector status of the responding CD8+ T cells.

Increased frequencies of Melan-A/MART-1–specific T cells were consistently observed also in patients' PBMCs stimulated with MART26-35A27L or MART27-35 in the presence of hLAG-3Ig (Fig. 2D and E, respectively). For patient P2, two rounds of peptide stimulation in the presence of hLAG-3Ig led to the generation of a T-cell culture in which the 63.07% of cells was represented by CD8+ Melan-A/MART-1–specific T cells. It is important to note that the hLAG-3Ig–mediated effect is presumably independent of the frequency of circulating antigen-specific T cells. In fact, hLAG-3Ig treatment increased the frequency of antigen-specific T cells also in individuals whose PBMCs reached a significant number of CD8+ T-cell precursors by peptide stimulation alone (Fig. 2A, donor D3; Fig. 2D and E, patient P1) as well as in those where peptide stimulation alone led to a low, barely detectable frequency of antigen-specific T cells (Fig. 2B, donor D5; Fig. 2E, patient P2).

Antigen-specific T lymphocytes generated in the presence of hLAG-3Ig release high levels of IFN-{gamma}. We next analyzed the functional activity of the cultured T cells known to contain antigen-specific CD8+ T cells by tetramer staining analysis. Because a significant difference, in terms of frequency, was observed between cells stimulated in the presence or absence of hLAG-3Ig, we asked whether the CD8+ T cells generated with hLAG-3Ig were also endowed with functional activity to exclude that they could indeed represent anergic CD8+ T cells or T lymphocytes with low antigen affinity and unable to be functionally triggered by their nominal antigen. To explore the specificity of the in vitro activated T cells, IFN-{gamma} ELISPOT assays were first done. The function of influenza matrix–specific CD8+ T cells was evaluated by analyzing IFN-{gamma} release in response to Flu58-66-loaded T2 cells (Fig. 3A ). This HLA-A*0201–restricted viral antigen is highly immunogenic, and specific IFN-{gamma} release could be detected after a single round of sensitization with the peptide alone (see Fig. 3A, left, donors D1 and D2). However, the addition of hLAG-3Ig to the lymphocyte culture strongly amplified the antigen-specific IFN-{gamma} release, and in all the tested cultures, the presence of hLAG-3Ig led to a number of specific T cells that exceeded the range limit of the ELISPOT assay (Fig. 3A, right).


Figure 3
View larger version (21K):
[in this window]
[in a new window]
  		Figure 3. Addition of soluble hLAG-3Ig to PBMC cultures of healthy donors or melanoma and colorectal cancer patients leads to the generation of a high number of functionally active antigen-specific T cells. A, PBMCs of healthy donors D1, D2, and D3 were subjected to one (D1) or two (D2 and D3) rounds of in vitro stimulation with HLA-A*0201–restricted Flu58-66 peptide and then analyzed in ELISPOT assay for the presence of IFN-{gamma}-secreting cells. In the T-cell stimulation assay, lymphocytes were incubated alone (column 1) or with T2 cells loaded with 2 µg/mL HLA-A*0201–restricted control peptide (HIV env117-125, column 2) or with Flu58-66 peptide (column 3). Cell cultures were done with or without the addition of 16 µg/mL hLAG-3Ig (top). B and C, PBMCs of healthy donors D4 and D5 and of melanoma patients P1 and P2 were cultured in vitro for 10 days with MART26-35A27L (B) or MART27-35 (C) peptide either alone or in the presence of 16 µg/mL hLAG-3Ig and then restimulated with peptide-pulsed, {gamma}-irradiated autologous PBMCs. The frequency of IFN-{gamma}-secreting cells was evaluated by IFN-{gamma} ELISPOT. For the T-cell stimulation assay, antigen-stimulated T cells were cultured with T2 cells loaded with 2 µg/mL HLA-A*0201–restricted control peptide (HIV env117-125, column 1), 2 µg/mL MART27-35 peptide (column 2), or 2 µg/mL MART26-35A27L peptide (column 3); HLA-A*0201+ Melan-A/MART-1+ Me501 melanoma cell line, alone (column 4) or in the presence of blocking A6-136 anti-HLA class I mAb (column 5). ND, not detected. D, PBMCs of colorectal cancer patient P4 were subjected to two rounds of in vitro stimulation with SVV-1 peptide and then analyzed in the ELISPOT assay for the presence of IFN-{gamma}-secreting cells. Cell culture was done with or without the addition of 16 µg/mL hLAG-3Ig. For the assay, lymphocytes were stimulated with T2 cells loaded with 2 µg/mL HLA-A*0201–restricted control peptide (HIV env117-125, column 1) or of SVV-1 peptide (column 2), HLA-A*0201+ survivin+ SW480 colon cancer cell line, alone (column 3) or in the presence of blocking anti-HLA class I A6-136 mAb (column 4). Data are expressed as the number of spots per well, depending on each experiment. >, number of spots in the wells exceeds counting limits. *, P < 0.05 (evaluated by Student's t test for unpaired samples), compared with the recognition of the same target in the absence of anti-HLA class I A6-136 mAb.

 
The role of hLAG-3Ig in the induction of tumor-specific reactivity was then evaluated. For two of four CD8+ T-cell cultures generated in vitro by stimulating HLA-A*0201+ melanoma patients' or donors' PBMCs with the highly immunogenic MART26-35A27L analogue peptide, no reactivity was detectable (Fig. 3B, left, D4 and P2), whereas the two additional cultures tested displayed significant release of cytokine in response to specific peptides (Fig. 3B, left, D5 and P1). When PBMCs of the same individuals were cultured with MART26-35A27L analogue peptide together with hLAG-3Ig, their specific reactivity was strongly enhanced (Fig. 3B, right, D5 and P1), and in the presence of hLAG-3Ig, specific IFN-{gamma} release was detected also in those PBMCs for which the culture with peptide alone failed to achieve functional specificity (Fig. 3B, right, D4 and P2). Moreover, all the Melan-A/MART-1–specific CD8+ T cells generated in the presence of hLAG-3Ig recognized their antigen when naturally processed by melanoma, as shown by the class I HLA–restricted recognition of a Melan-A/MART-1+, HLA-A*0201+ melanoma cell line (Fig. 3B, right, columns 4 and 5).

Similar results were also obtained by stimulating T cells from melanoma patients and healthy donors with the wild-type MART27-35 nonapeptide (Fig. 3C). In fact, when PBMCs from melanoma patients and healthy donors were stimulated with the wild-type epitope, the addition of hLAG-3Ig to the cell cultures induced a significant amplification of IFN-{gamma} release in response to antigen. All the T-cell cultures recognized their nominal antigen when loaded on T2 cells (Fig. 3C, right, columns 2 and 3). Partially because of its low binding affinity to HLA-A2.1 molecule, the immunogenicity of the wild-type MART27-35 peptide is known to be weaker than that of the modified MART26-35 A27L decapeptide. For donor 5 and patient 1, the frequency of specific T cells obtained by the stimulation with the wild-type peptide was low, not sufficient to lead to a strong tumor recognition, and T cells generated from these PBMCs showed only borderline tumor recognition (Fig. 3, D5 and P1). Conversely, for donor 4 and patient 2 in front of a quite high number of MART-1-specific T cells, no tumor recognition occurred, suggesting that LAG-3 molecules might have expanded preexiting T cells bearing TCR with low affinity/avidity for their nominal antigen not sufficient to be activated by melanoma cells (Fig. 3, D4 and P2).

Therefore, the presence of hLAG-3Ig led to the generation of Melan-A/MART-1–specific T cells in all the cultures tested, independently from the source of lymphocytes (patients' or healthy donors' PBMCs) and from the type of Melan-A/MART-1 peptide used (the MART26-35A27L analogue decapeptide or the wild-type MART27-35 nonapeptide).

Considering other TAA models, T cells generated in vitro from PBMCs of a HLA-A*0201+ colorectal cancer patient by peptide stimulation in the presence of hLAG-3Ig showed an increased release of IFN-{gamma} in response to peptide-loaded T2 cells and also to survivin+, HLA-A*0201+ SW480 colon cancer cell line (Fig. 3D, left and right, see legend).

In conclusion, all data obtained with IFN-{gamma} ELISPOT assays confirmed that hLAG-3Ig enhanced the generation of peptide-specific T cells that were endowed with functional activity and that, in the case of tumor-derived peptides, had the ability to recognize antigen-positive tumor cells. Such a functional activity of the hLAG-3Ig recombinant protein in enhancing the generation of peptide-specific T cells in vitro was due to the LAG-3 molecule itself and not dependent by the IgG portion of the recombinant protein. In fact, neither human purified IgG Fc fragments nor human purified whole IgG proteins when added during the T-cell culture conditions were able to significantly increase the induction of antigen-specific T cells in vitro (for details, see Supplementary Information).

hLAG-3Ig favors the generation of anti-Melan-A/MART-1 T cells with a type 1 pattern of cytokine release that includes IL-2. To better characterize the type of anti-Melan-A/MART-1 CD8+ T cell responses, antigen-stimulated T lymphocytes obtained from melanoma patients P1 and P2, cultured alone or in the presence of peptide-loaded T2 cells or Me501 melanoma cell line, were studied for the release of Th1/Th2 cytokines by CBA assay (Table 1 ). T cells generated in the presence of hLAG-3Ig in both patients produced more cytokines than the corresponding T cells grown with peptide alone, although with some differences in their total levels due to individual variations. Moreover, a type 1 cytokine pattern that included tumor necrosis factor-{alpha} (TNF-{alpha}) and IL-2 production could be identified for both patients upon T-cell stimulation with nominal peptide. Because melanoma cells probably express limited amount of antigen, and because they did not bear other relevant costimulatory molecules, they failed to fully activate T cells, and these Mart-1-specific T cells did not release IL-2 upon tumor stimulation.


View this table:
[in this window]
[in a new window]
  		Table 1. Different cytokine profile of peptide-stimulated T cells as evaluated by Th1/Th2 CBA assay

 
CD8+ T cells generated in the presence of hLAG-3-Ig are cytotoxic and express terminally differentiated effector phenotype. To exert their antitumor reactivity, tumor-specific CD8+ T cells should be able to potentially home into tumor tissues and be cytotoxic. We therefore tested whether the CD8+ T cells generated by peptide stimulation and hLAG-3Ig displayed cytotoxic functions and were characterized by a final effector phenotype. Perforin is a pore-forming protein produced and exocytosed in cytoplasmic granules by effector T lymphocytes after encountering target cells. Thus, to determine cell-mediated cytotoxicity, we investigated the release of perforin by our activated T cells: its production by antigen-stimulated T cells was evaluated by a specific ELISPOT assay. As shown in Fig. 4A and B for melanoma patient P1, PBMCs stimulated either with MART26-35A27L (Fig. 4A) or with wild-type MART27-35 epitope (Fig. 4B) in the presence of hLAG-3Ig were able to release perforin in response to T2 cells loaded with either peptide (column 2 and 3, respectively), but not with a HLA-A*0201–restricted, HIV-derived control peptide HIVenv117-125 (column 1). The frequency of CTLs in MART26-35A27L-stimulated population was higher than in the MART27-35-stimulated one. Moreover, both populations released perforin in response to Me501 melanoma cell line (column 4), and this CTL activity was inhibited by the anti-class I HLA mAb A6-136 (column 5).


Figure 4
View larger version (18K):
[in this window]
[in a new window]
  		Figure 4. Antigen-specific CD8+ T cells, generated in the presence of hLAG-3Ig, maintain CTL activity and the features of final effectors. A and B, PBMCs of melanoma patient P1, subjected to two rounds of stimulation with MART26-35A27L (5A) or MART27-35 (5B) peptide in the presence of hLAG-3Ig, were analyzed for their CTL activity by perforin ELISPOT. In the T-cell activation assay, lymphocytes were cultured with: T2 cells loaded with 2 µg/mL HLA-A*0201–restricted control peptide (HIV env117-125, column 1), 2 µg/mL MART27-35 peptide (column 2), or 2 µg/mL MART26-35A27L peptide (column 3); HLA-A*0201+ Melan-A/MART-1+ Me501 melanoma cell line, alone (column 4) or in the presence of blocking A6-136 anti-HLA class I mAb (column 5). C and D, frequency of antigen-specific CTLs in PBMCs of healthy donors D6 and D7, stimulated once (D7) or twice (D6) with Flu58-66 peptide in the presence of hLAG-3Ig. For the T-cell activation assay, lymphocytes were incubated alone (1) or in the presence of T2 cells loaded with HLA-A*0201–restricted control peptide (HIV env117-125, 2) or with Flu58-66 peptide (3). Data are expressed as number of spots per well, depending on each experiment. E, phenotypic analysis of in vitro generated MART26-35A27L–specific CD8+ T cells after two rounds of in vitro stimulation. Activated T lymphocytes of melanoma patient P1 were stained with phycoerythrin-conjugated MART26-35A27L/HLA-A*0201 tetramers, PerCP-conjugated anti-CD8 mAb, and with FITC-conjugated anti-CD28, anti-CD45RA, or anti-CCR7 mAb and analyzed on a flow cytometer. After gating on tetramer+ CD8+ cells, the expression of the indicated surface molecules on this subpopulation was determined. The percentage of positive cells for each marker is indicated in each panel. Top, phenotype of cells cultured with the peptide alone; bottom, phenotype of cells cultured with the peptide in the presence of hLAG-3Ig.

 
Perforin ELISPOT was done also on influenza matrix–specific CD8+ T lymphocytes cultured in the presence of hLAG-3Ig. As an example, healthy donors' PBMCs stimulated with Flu58-66 peptide (Fig. 4C and D, donors D7 and D4, respectively) released perforin in response to T2 cells loaded with the specific peptide (C and D, column 3) but not with a HLA-A*0201–restricted, HIV-derived control peptide HIVenv117-125 (column 2). Basal release of perforin was evaluated by incubating stimulated T lymphocytes only in the presence of medium (column 1).

The phenotype of antigen-specific T cells generated in the presence of hLAG-3Ig was also analyzed. As shown in Fig. 4E, T cells stimulated with MART26-35A27L did show positive staining for CD45RA, and the addition of the recombinant protein to the cell culture induced a significant reduction of CCR7 and CD28 surface expression in the gated CD8+ tetramer+ T-cell subpopulation (Fig. 4E, bottom and top, respectively), indicating the acquisition of a phenotype of terminally differentiated effector cells.

Adjuvant effect of hLAG-3Ig in the generation of antigen-specific CD8+ T cell is preserved in the absence of CD4+CD25+ regulatory T cells. Given the recent evidence suggesting a functional role of LAG-3 in T regulatory cells at least in the mouse system (15), we asked whether CD4+CD25+ T regulatory cells could be the main target of the mechanisms by which hLAG-3Ig recombinant protein exerts its adjuvant activities in the induction of antigen-specific T lymphocytes. Indeed, at least in mice, LAG-3 engagement seems to be necessary for suppressive activity of T regulatory cells (15). Soluble LAG-3 added during PBMC stimulation might potentially compete for MHC class II binding with membrane-bound LAG-3 molecule expressed on the surface of T regulatory cells, thereby inhibiting T regulatory cells activity and thus promoting effector T-cell expansion. Therefore, we investigated whether the T-cell promoting effect of hLAG-3Ig was dependent on the presence of CD4+CD25+ T regulatory cells. Following depletion of CD4+CD25+ T cells, freshly isolated PBMCs of different healthy donors were subjected to two rounds of in vitro stimulation with MART26-35A27L (Fig. 5A ) and MART27-35 (Fig. 5B) peptides in the presence or in the absence of hLAG-3Ig (Fig. 5, left and right, respectively). hLAG-3Ig treatment strongly increased the frequency of IFN-{gamma}-releasing antigen-specific T cells even in CD4+CD25+-depleted PBMCs. As shown in Fig. 5, CD4+CD25+-depleted PBMCs stimulated twice with MART26-35A27L (Fig. 5A) and MART27-35 (Fig. 5B) peptides in the presence of hLAG-3Ig and released high levels of IFN-{gamma} in response to T2 cells loaded with either peptide (column 2 and 3, respectively) but not with a HLA-A*0201–restricted, HIV-derived control peptide HIVenv117-125 (column 1). Conversely, the same stimulations done in the absence of hLAG-3Ig did not show a significant and specific release of IFN-{gamma} in response to both antigens. Tetramer analysis confirmed ELISPOT results (data not shown). The addition of LAG-3 induced the expansion of MART-1-specific T cells; however, in this case, as previously showed also for donor D4 and patient P2 (Fig. 3), the induced T cells did not recognized the HLA-A2-positive melanoma (Fig. 5A and B, right), confirming the possibility that LAG-3 molecules might have expanded preexiting T bearing a TCR with low affinity/avidity for their nominal antigen.


Figure 5
View larger version (13K):
[in this window]
[in a new window]
  		Figure 5. Depletion of CD4+CD25+ T cells does not affect the adjuvant function of hLAG-3Ig in the generation of an antigen-specific T-cell response. After depletion of CD4+CD25+ T cells, freshly isolated PBMCs of healthy donors were stimulated twice with MART26-35A27L (A) and MART27-35 (B) peptides in the presence or in the absence of hLAG-3Ig (left and right, respectively) and then analyzed in ELISPOT assay for the presence of IFN-{gamma}-secreting cells. In the T-cell stimulation assay, lymphocytes were incubated with T2 cells loaded with 2 µg/mL HLA-A*0201–restricted control peptide (HIV env117-125, column 1), 2 µg/mL MART27-35 peptide (column 2), or 2 µg/ml MART26-35A27L peptide (column 3); HLA-A*0201+ Melan-A/MART-1+ Me501 melanoma cell lines, alone (column 4) or in the presence of blocking anti-HLA class I mAb (column 5).

 
Based on these findings, it is likely that hLAG-3Ig exerts its activity, targeting cells other than T regulatory, although we can not formally rule out the possibility that LAG-3 molecule may also indirectly affect CD4+CD25+ functions.

Soluble LAG-3 (hLAG-3Ig) activates peripheral blood APCs, inducing the release of chemokines and proinflammatory cytokines. It has been extensively shown that the hLAG-3Ig induced dendritic cell activation through a direct interaction with the HLA class II molecules expressed by the APC, whereas no major involvement of the Fc potion of the hLAG-3Ig molecules was found in mediating such a functional activity of hLAG-3Ig molecules (18, 19). To define the major subset of cells directly interacting with the recombinant protein and to identify the molecular and cellular network leading to the amplification of the immune response, the effect of hLAG-3Ig treatment was evaluated on the phenotype and functional activity of monocytes, dendritic cells, and B cells included in such analysis because they have been recently shown to be efficient APCs, able to stimulate strong antigen-specific T-cell responses (28).

PBMCs of healthy donors were cultured for 48 hours in the presence of 3 µg/mL MART26-35A27L peptide and 16 µg/mL hLAG-3Ig, as previously done for antigen stimulation. Cells were harvested, and the activation status of the different subpopulations of APCs present in the whole culture was analyzed by flow cytometry for the surface expression of CD80, CD83, and CD86 molecules; supernatants of the same cell cultures were evaluated for the presence of cytokines and chemokines.

Exploiting the expression of their distinctive cell surface markers, we identified CD14+ monocytes, CD19+ B lymphocytes, and Lin–/CD123low/high PBDCs. As shown in Table 2 , treatment with hLAG-3Ig induced significant up-regulation of CD83 and CD86 on all APC populations. In particular, CD83 expression levels ranged from 1.3% to 20.4% on PBDCs and from 0.3% to 18.6% on monocytes, whereas CD86 ranged from 45.4% to 70.4% on PBDCs and from 65.3% to 81.7% on monocytes. No increase in CD80 expression was detectable in any of the cell subsets. These phenotypic changes in the profile of costimulatory molecules expressed by each APC subset were confirmed on isolated APCs purified from PBMCs and exposed in vitro to hLAG-3Ig for 48 hours (data not shown).


View this table:
[in this window]
[in a new window]
  		Table 2. Antigen stimulation of human PBMCs in the presence of hLAG-3Ig induces expression of maturation markers on the surface of different APC subpopulations

 
To characterize the immune modulation induced by hLAG-3Ig treatment, the extent of cytokine and chemokine release in the same PBMC cultures was evaluated by CBA assays (Table 3 ). Antigen stimulation in the presence of hLAG-3Ig strongly increased the production of RANTES, TNF-{alpha}, IL-4, IL-6, and IL-1ß and, to a lesser extent, of IFN-{gamma}. IP-10 and MIG, ligands for the same chemokine receptor CXCR3, were still detectable at high levels although down-regulated compared with those found in cultures of PBMCs with peptide alone.


View this table:
[in this window]
[in a new window]
  		Table 3. Stimulation of human PBMCs by hLAG-3Ig induces the release of an activating pattern of proinflammatory cytokines and chemokines

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
In the present study, we show that human soluble LAG-3 protein (hLAG-3Ig) can act as an adjuvant in the induction of an antiviral and antitumor immune response, enhancing the expansion of antigen-specific CD8+ T lymphocytes characterized by CTL activity, release of Tc1 cytokines, and final effector memory phenotype. Our data, by extending to a human setting previous findings obtained in animal tumor models (20, 23, 24), indicate that LAG-3 molecule, physiologically produced by human cells (11) and characterized by in vitro strong immunostimulatory properties (18), when used as a soluble recombinant protein, could indeed satisfy the major requirements for a safe and effective adjuvant for vaccine treatment in cancer patients.

In our study, four different antigens have been used to test the in vitro adjuvant features of hLAG-3Ig. These antigens included the influenza matrix protein–derived Flu58-66 peptide, the TAA peptide MART27-35, its MART26-35A27L analogue, and the survivin-derived SVV-195-104 peptide. The in vitro and in vivo immunologic behavior of these antigens has been already extensively described and discussed (26, 27, 29, 30). We were able to show that hLAG-3Ig added in vitro to the T-cell cultures consistently induced a rapid and better proliferation of T cells. This enhanced proliferation was not due to a non-specific mechanism of activation but indeed represented the selective expansion of antigen-reactive T cells. Furthermore, we showed that these peptide-specific T lymphocytes, generated in the presence of hLAG-3Ig, were characterized by a strong CTL activity and by enhanced functional properties.

The analysis of cytokines released by the peptide-specific T cells upon peptide stimulation did show that in all the Melan-A/MART-1–stimulated cultures hLAG-3Ig strongly promoted a Tc1-like pattern of cytokine release characterized by the production of higher levels of IFN-{gamma}, TNF-{alpha}, and IL-2 compared with cultures done with the peptide alone. Indeed, tumor-specific type 1 immunity, which includes tumor antigen-specific Th1 and Tc1 cells, plays a critical role in tumor eradication (31, 32), whereas in cancer patients, a tumor immune response skewed toward a type 2 immunity has been associated to persistence of an active disease (33). Of note, in a melanoma patient, peptide-specific T cells also released IL-4, and this production was further increased upon hLAG-3Ig treatment. This observation, although apparently contradictory, may be explained considering the requirement of IL-4 produced by CD8+ T cells in the generation of tumor-specific Th1 cells (34, 35). In agreement with their complete fully activated status, the antigen-specific T cells generated in the presence of hLAG-3Ig did show a final effector memory phenotype (CCR7–CD45RA+ and CD28low), therefore suggesting that they should be potentially able to home into inflamed tissues where they could exert their antigen-specific cytotoxic activity.

The increased frequency of antigen specificity detected in hLAG-3Ig–stimulated cultures was observed either with viral-associated antigens or TAAs in PBMCs of healthy donors or of cancer patients, suggesting that hLAG-3Ig allowed efficient priming and expansion of naive T cells and complete activation of memory T-cell subset. Treatment with hLAG-3Ig, therefore, may potentially succeed (a) in cancer vaccine by expanding preexisting T cells and inducing reacquisition of effector functions and (b) in a prophylactic vaccination when the induction of a primary CTL immune response is required.

In the case of melanoma-associated antigen Melan-A/MART-1, a significant increase in antigen-specific T cells was seen either after stimulation with the highly immunogenic MART26-35A27L peptide analogue or with the less immunogenic natural counterpart MART27-35, therefore highlighting the potential role of hLAG-3Ig in strengthening the response against antigens usually poorly recognized by the immune system.

In general anti-MART-1-specific T cells generated in the presence of hLAG-3Ig were also able to recognize tumor cells, suggesting that the affinity of these T cells for their corresponding nominal antigen was strong enough to ensure the recognition of antigens naturally processed by tumor cells. However, in few cases, this tumor-recognition failed to occur. Indeed, tumor recognition may be dependent by the original TCR repertoire characteristic of each single patient/donor, and hLAG-3Ig mainly worked in expanding all the possible specificities already present in each PBMC. When such specificities included T cells with appropriate TCR avidity/affinity, then the resulting T-cell cultures were also endowed with tumor recognition ability. Although this hypothesis could be proved only by clonal analysis of the affinity/avidity of each T cell generated in the presence or in the absence of hLAG-3Ig; nevertheless, our data still proved that hLAG-3Ig increased the frequency of peptide-specific T cells and expanded T cells endowed with tumor recognition activities if they were already present in the original PBMCs.

Due to unavailability of reliable reagents for tetramer staining, we were unable to document the expansion of T cells expressing survivin-specific TCR in hLAG-3Ig–treated cultures. Nonetheless, even for this universal tumor antigen, we showed the ability of hLAG-3Ig treatment to cause an overexpansion of T cells releasing INF-{gamma} in response to survivin peptide stimulation, and, more importantly, we were able to show the specific recognition of naturally processed antigen after only two rounds of in vitro stimulation, again validating the adjuvant role of hLAG-3Ig for an additional TAA.

Because LAG-3 protein binds HLA class II molecules (10), it is unlikely that the adjuvant action of hLAG-3Ig involved a direct interaction with naive or memory T cells. In agreement with mouse vaccination studies suggesting a possible involvement of APCs in mediating the adjuvant activities of LAG-3 molecules (24, 36), our data confirm that early antigen stimulation of human PBMCs in the presence of hLAG-3Ig induced a more mature phenotype in APCs present in the peripheral blood. Indeed, monocytes, B cells, and PBDCs showed up-regulation of CD83 and CD86, whereas no or very low effect was seen on CD80 expression. These data could contribute to the understanding of the complex mechanism of action of LAG-3 protein. CD83-positive, mature APCs are licensed to efficiently present peptides even in the first phases of stimulation. In addition, through a preferential up-regulation of CD86 compared with CD80, LAG-3 molecule might favor the induction of an activating pathway, which involves CD86-CD28 pairing while limiting the CD80-CD28 contacts described as mainly involved in interaction with T regulatory cells (37, 38).

Our in vitro stimulation assays could show that at 48 hours of peptide stimulation, the presence of hLAG-3Ig promoted the release, in the culture medium, of higher levels of endogenous IL-4 and other proinflammatory cytokines, like IL-6, TNF-{alpha}, and IL-1ß. Although IL-4 is crucial for Th1 cell priming in the early steps during the generation of an antitumor immune response and it is required to sustain dendritic cell differentiation from monocytes (34, 35), cytokines like IL-1ß and TNF-{alpha} are involved in promoting costimulation between dendritic cells and T cells, therefore enhancing the extent of antigen-specific reactivity (39). Strangely enough, this type 1 immunity did not include any detectable level of IL-12. However, it is still possible that different kinetic points need to be considered, or that all the cytokine produced was immediately used by T cells. In fact, using an intracellular cytokine flow cytometry–based assay, it has been recently shown that IL-12 could be produced by a minority of the activated dendritic cells (40). Huge amounts of IL-6 were induced in stimulations that include hLAG-3Ig protein. Indeed, it has been recently shown that IL-6 favors the shift from neutrophils to monocyte recruitment at site of inflammation and plays a role in directing the transition between innate and acquired immune response (41, 42). Moreover, although with a yet unknown mechanism, IL-6 produced by dendritic cells has been described as a crucial cytokine in hampering the suppressor activity mediated by CD4+CD25+ T cells (43). In addition to the above described cytokines, the presence of hLAG-3Ig led also to the enrichment of inflammatory chemokines, some of which could be directly produced by the activated dendritic cells (44). RANTES was strongly up-regulated in hLAG-3Ig–treated T-cell cultures. This member of the CC chemokine family of proteins plays an essential role in inflammation by recruiting T cells, macrophages, and eosinophils to inflammatory sites. RANTES coexpressed with other costimulating molecules by APCs has been shown to elicit strong antitumor and recall responses as well as tumor-specific CTL activity in mouse models (45). The milieu of cytokines and inflammatory chemokines induced in the presence of hLAG-3Ig in the early phases of T-cell induction might be responsible of sustaining and supporting the selective expansion of a type 1 tumor-specific immunity. Moreover, the activation pattern of blood APCs and the presence of high amount of IL-6 together with the ability of finally committed T cells to release IL-2 in response to antigen stimulation might be of help in neutralizing the activity of T regulatory cells.

Both basic and translational researches are now aimed at the identification of more potent TRL 1-9 agonists and at defining their role in linking innate and acquired immunity (46–48). Here, we showed that soluble LAG-3, a molecule of human origin, may function as an adjuvant in enhancing tumor-specific responses, and that its activity is likely to be higher than that of type A and type B oligodeoxynucleotides containing unmethylated CG dinucleotides (CpG-A and CpG-B oligodeoxynucleotides) tested under similar conditions (49). In fact, in our experiments, we were able to detect specific anti-Melan-A/Mart-1 or anti-Flu reactivity in PBMCs without the need of enriching the starting PBMC population with CD8+ T cells. Moreover, CpG-A and CpG-B oligodeoxynucleotides have been reported to preferentially target plasmacytoid dendritic cells and B cells, respectively, with CpG-A shown to be superior in expanding preexisting T cells while CpG-B in inducing primary CTL immune response. Our data indicated that the LAG-3 molecule equally activated different APCs in peripheral blood of healthy donors and cancer patients, including PBDCs and B cells, and sustained both primary and recall T-cell responses, combining therefore in a single molecule the adjuvant effects of both CpG-A and CpG-B.

Although the in vivo adjuvant activity of hLAG-3Ig remains to be addressed, nevertheless, it has already been shown that LAG-3 does exist as natural soluble molecule in sera of healthy individuals and in patients as well. Moreover, in patients, the level of natural soluble LAG-3 in sera is associated with a cellular immune response, and high levels seemed to be protective in conditions where Th1 responses are an essential component of immune protection, such as tuberculosis or cancer (21, 50).

In conclusion, our data validate the immunostimulatory activity of hLAG-3Ig in inducing TAA-specific CD8+ T-cell responses in a human setting, and they strongly support the use of this recombinant protein as a promising candidate adjuvant for cancer vaccination.


   Acknowledgments
 
Grant support: ITALY-USA Program on Immunology and Immunotherapy of Cancer (Italian Ministry of Health), Associazione Italiana per la Ricerca contro il Cancro (Milan).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


   Footnotes
 
Note: Supplementary data for this article are available at Cancer Research Online (http://cancerres.aacrjournals.org/).

Received 8/26/05. Revised 1/12/06. Accepted 2/ 1/06.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Parmiani G, Castelli C, Dalerba P, et al. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J Natl Cancer Inst 2002;94:805–18.[Abstract/Free Full Text]
  2. Rosenberg SA. Progress in human tumor immunology and immunotherapy. Nature 2001;411:380–4.[CrossRef][Medline]
  3. Marciani DJ. Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity. Drug Discov Today 2003;8:934–43.[CrossRef][Medline]
  4. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000;74:181–273.[Medline]
  5. Rivoltini L, Carrabba M, Huber V, et al. Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction. Immunol Rev 2002;188:97–113.[CrossRef][Medline]
  6. Nishijawa H, Jager E, Ritter G, Old LJ, Gnajatic S. CD4+Cd25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients. Blood 2005;106:1008–11.[Abstract/Free Full Text]
  7. Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD4+ CD25+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 1999;163:5211–8.[Abstract/Free Full Text]
  8. Antony PA, Piccirillo CA, Akpinarli A, et al. CD8+ T cell immunity against tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol 2005;174:2591–601.[Abstract/Free Full Text]
  9. Triebel F, Jitsukawa S, Baixeras E, et al. LAG-3, a novel lymphocyte activation gene closely related do CD4. J Exp Med 1990;171:1393–405.[Abstract/Free Full Text]
  10. Baixeras E, Huard B, Miossec C, et al. Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens. J Exp Med 1992;176:327–37.[Abstract/Free Full Text]
  11. Huard B, Gaulard P, Faure F, Hercend T, Triebel F. Cellular expression and tissue distribution of the human LAG-3-encoded protein, a MHC class II ligand. Immunogenetics 1994;39:213–7.[Medline]
  12. Triebel F. LAG-3: a regulator of T-cell and DC responses and its use in therapeutic vaccination. Trends Immunol 2003;24:619–22.[CrossRef][Medline]
  13. Hannier S, Tournier M, Bismuth G, Triebel F. CD3/TCR complex-associated lymphocyte activation gene-3 molecules inhibit CD3/TCR signaling. J Immunol 1998;161:4058–65.[Abstract/Free Full Text]
  14. Workman CJ, Dugger KJ, Vignali DA. Molecular analysis of the negative regulatory function of lymphocyte activation gene-3. J Immunol 2002;169:5392–5.[Abstract/Free Full Text]
  15. Huang CT, Workman CJ, Flies D, et al. Role of LAG-3 in regulatory T cells. Immunity 2004;21:503–13.[CrossRef][Medline]
  16. Workman CJ, Vignali DA. Negative regulation of T cell homeostasis by lymphocyte activation gene-3 (CD223). J Immunol 2005;74:688–95.
  17. Macon-Lemaitre L, Triebel F. The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells. Immunology 2005;115:170–8.[CrossRef][Medline]
  18. Andreae S, Piras F, Burdin N, Triebel F. Maturation and activation of dendritic cells induced by lymphocyte activation gene-3 (CD223). J Immunol 2002;168:3874–80.[Abstract/Free Full Text]
  19. Andreae S, Buisson S, Triebel F. MHC class II signal transduction in human dendritic cells induced by a natural ligand, the hLAG-3Ig protein (CD223). Blood 2003;102:2130–7.[Abstract/Free Full Text]
  20. El Mir S, Triebel F. A soluble lymphocyte activation gene-3 molecule used as a vaccine adjuvant elicits greater humoral and cellular immune responses to both particulate and soluble antigens. J Immunol 2000;164:5583–9.[Abstract/Free Full Text]
  21. Triebel F, Hacene K, Pichon MF. A soluble lymphocyte activation gene-3 (sLAG-3) protein as a prognostic factor in human breast cancer expressing estrogen or progesterone receptors. Cancer Lett 2005 Jun 7 [Epub ahead of print].
  22. Demeure CJ, Wolfers J, Martin-Garcia N, Gaulard P, Triebel F. T lymphocytes infiltrating various tumor types express the MHC class II ligand lymphocyte activation gene-3 (LAG-3): role of LAG-3/MHC class II interactions in cell-cell contacts. Eur J Cancer 2001;73:1709–15.
  23. Prigent P, El mir S, Dréano M, Triebel F. Lymphocyte activation gene-3 induces tumor regression and antitumor immune responses. Eur J Immunol 1999;29:3867–76.[CrossRef][Medline]
  24. Cappello P, Triebel F, Iezzi M, et al. LAG-3 enables DNA vaccination to persistently prevent mammary carcinogenesis in HER-2/neu transgenic BALB/c mice. Cancer Res 2003;63:2518–25.[Abstract/Free Full Text]
  25. Huard B, Prigent P, Pages F, Bruniquel D, Triebel F. T cell major histocompatibility complex class II molecules down-regulate CD4+ T cell clone responses following LAG-3 binding. Eur J Immunol 1996;26:1180–6.[Medline]
  26. Casati C, Dalerba P, Rivoltini L, et al. The apoptosis inhibitor protein survivin induces tumor-specific CD8+ and CD4+ T cells in colorectal cancer patients. Cancer Res 2003;63:4507–15.[Abstract/Free Full Text]
  27. Romero P, Valmori D, Pittet MJ, et al. Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma. Immunol Rev 2002;188:81–96.[CrossRef][Medline]
  28. Lapointe R, Bellemare-Pelletier A, Housseau F, Thibodeau J, Hwu P. CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. Cancer Res 2003;63:2836–43.[Abstract/Free Full Text]
  29. Rivoltini L, Kawakami Y, Sakaguchi K, et al. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J Immunol 1995;154:2257–65.[Abstract]
  30. Andersen MH, Pedersen LO, Capeller B, Brocker EB, Becker JC, thor Straten P. Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res 2001;61:5964–8.[Abstract/Free Full Text]
  31. Nishimura T, Iwakabe K, Sekimoto M, et al. Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J Exp Med 1999;190:617–27.[Abstract/Free Full Text]
  32. Chamoto K, Kosaka A, Tsuji T, et al. Critical role of the Th1/Tc1 circuit for the generation of tumor-specific CTL during tumor eradication in vivo by Th1-cell therapy. Cancer Sci 2003;94:924–8.[CrossRef][Medline]
  33. Tatsumi T, Kierstead LS, Ranieri E, et al. Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J Exp Med 2002;196:619–28.[Abstract/Free Full Text]
  34. Schuler T, Kammertoens T, Preiss S, Debs P, Noben-Trauth N, Blankenstein T. Generation of tumor-associated cytotoxic T lymphocytes requires interleukin 4 from CD8(+) T cells. J Exp Med 2001;194:1767–75.[Abstract/Free Full Text]
  35. Eguchi J, Kuwashima N, Hatano M, et al. IL-4-transfected tumor cell vaccines activate tumor-infiltrating dendritic cells and promote type-1 immunity. J Immunol 2005;174:7194–201.[Abstract/Free Full Text]
  36. Carlo ED, Cappello P, Sorrentino C, et al. Immunological mechanisms elicited at the tumour site by lymphocyte activation gene-3 (LAG-3) versus IL-12: sharing a common Th1 anti-tumour immune pathway. J Pathol 2005;205:82–91.[CrossRef][Medline]
  37. Sharpe AH, Freeman GJ. The B7-28 superfamily. Nat Rev Immunol 2002;2:116–26.[CrossRef][Medline]
  38. Zheng Y, Manzotti CN, Liu M, Burke F, Mead KI, Sansom DM. CD86 and CD80 differentially modulate the suppressive function of human regulatory T cells. J Immunol 2004;172:2778–84.[Abstract/Free Full Text]
  39. Bai L, Beckhove P, Feuerer M, et al. Cognate interactions between memory T cells and tumor antigen-presenting dendritic cells from bone marrow of breast cancer patients: bidirectional cell stimulation, survival and antitumor activity in vivo. Int J Cancer 2003;103:73–83.[CrossRef][Medline]
  40. Muller-Berghaus J, Olson WC, Moulton RA, Knapp WT, Schadendorf D, Storkus WJ. IL-12 production by human monocyte-derived dendritic cells: looking at the single cell. J Immunother 2005;28:306–13.[Medline]
  41. Kaplanski G, Marin V, Montero-Julian F, Mantovani A, Farnarier C. IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation. Trends Immunol 2003;24:25–9.[CrossRef][Medline]
  42. McLoughlin RM, Jenkins BJ, Grail D, et al. IL-6 trans-signaling via STAT3 directs T cell infiltration in acute inflammation. Proc Natl Acad Sci U S A 2005;102:9589–94.[Abstract/Free Full Text]
  43. Pasare C, Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 2003;299:1033–6.[Abstract/Free Full Text]
  44. Sallusto F, Lanzavecchia A. Understanding dendritic cell and T-lymphocyte traffic through the analysis of chemokine receptor expression. Immunol Rev 2000;177:134–40.[CrossRef][Medline]
  45. Kutubuddin M, Federoff HJ, Challita-Eid PM, et al. Eradication of pre-established lymphoma using herpes simplex virus amplicon vectors. Blood 1999;93:643–54.[Abstract/Free Full Text]
  46. Re F, Strominger JL. IL-10 released by concomitant TRL2 stimulation blocks the induction of a subset of Th1 cytokines that are specifically induced by TRL4 or TRL3 in human dendritic cells. J Immunol 2004;173:7548–55.[Abstract/Free Full Text]
  47. Napolitani G, Rinaldi A, Bertoni F, Sallustro F, Lanzavecchia A. Selected Toll-Like receptor agonist combinations synergistically trigger a T helper type-1-polarizing program in dendritic cells. Nat Immunol 2005;6:769–76.[CrossRef][Medline]
  48. Speiser DE, Lienard D, Rufer N, et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 2005;115:739–46.[CrossRef][Medline]
  49. Rothenfusser S, Hornung V, Ayyoub M, et al. CpG-A and CpG-B oligonucleotides differentially enhance human peptide-specific primary and memory CD8+ T-cell responses in vitro. Blood 2004;103:2162–9.[Abstract/Free Full Text]
  50. Lienhardt C, Azzurri A, Amedei A, et al. Active tuberculosis in Africa is associated with reduced Th1 and increased Th2 activity in vivo. Eur J Immunol 2002;32:1605–15.[CrossRef][Medline]



This article has been cited by other articles:


Home page
 J. Immunol.Home page
C. Casati, C. Camisaschi, L. Novellino, A. Mazzocchi, F. Triebel, L. Rivoltini, G. Parmiani, and C. Castelli
Human Lymphocyte Activation Gene-3 Molecules Expressed by Activated T Cells Deliver Costimulation Signal for Dendritic Cell Activation
J. Immunol., March 15, 2008; 180(6): 3782 - 3788.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
C. Brignone, C. Grygar, M. Marcu, K. Schakel, and F. Triebel
A Soluble Form of Lymphocyte Activation Gene-3 (IMP321) Induces Activation of a Large Range of Human Effector Cytotoxic Cells
J. Immunol., September 15, 2007; 179(6): 4202 - 4211.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Casati, C.
Right arrow Articles by Castelli, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Casati, C.
Right arrow Articles by Castelli, C.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online